Earnings summaries and quarterly performance for Pacira BioSciences.
Executive leadership at Pacira BioSciences.
Board of directors at Pacira BioSciences.
Research analysts who have asked questions during Pacira BioSciences earnings calls.
Hardik Parikh
JPMorgan Chase & Co.
3 questions for PCRX
Also covers: RPRX, VKTX
Leszek Sulewski
Truist Securities
3 questions for PCRX
Also covers: AKBA, AMRX, ANIP +6 more
Gary Nachman
Raymond James
2 questions for PCRX
Also covers: ABBV, ACHV, ADMA +9 more
Oren Livnat
H.C. Wainwright
2 questions for PCRX
Also covers: ANIP, AVDL, CARA +7 more
Serge Belanger
Needham & Company
2 questions for PCRX
Also covers: AMPH, ARQT, BCRX +12 more
Anish Nikhanj
RBC Capital Markets
1 question for PCRX
Also covers: APTO, CRMD, EXEL +6 more
David Amsellem
Piper Sandler Companies
1 question for PCRX
Also covers: ABBV, ALKS, AMGN +27 more
Denis Reznik
Raymond James
1 question for PCRX
Also covers: AQST, INMB, VERU
Douglas Miehm
RBC Capital Markets
1 question for PCRX
Also covers: ACB, AUPH, BHC +2 more
Gregory Renza
RBC Capital Markets
1 question for PCRX
Also covers: ACAD, ADCT, AGIO +12 more
John Gionco
Needham & Co.
1 question for PCRX
Also covers: AMPH, CYTK, TRVI
Tejas Wein
Raymond James
1 question for PCRX
Also covers: FOLD
Recent press releases and 8-K filings for PCRX.
Pacira BioSciences Discusses Product Portfolio, 5 by 30 Plan, and Pipeline at Conference
PCRX
Guidance Update
Share Buyback
New Projects/Investments
- Pacira BioSciences projects over $700 million in revenue and a couple hundred million in adjusted EBITDA for the current year, having also repurchased $100 million worth of stock over the last couple of quarters.
- The company's 5 by 30 Plan targets 10% CAGR top-line growth over the next five years, a 5% improvement in gross margin from 2024 levels, and aims for 3 million patients to benefit from its therapies by 2030.
- The No Pain Act has been implemented, providing separate reimbursement for Exparel at ASP + 6 in outpatient settings for CMS patients, which is expected to reinvigorate growth.
- Key pipeline developments include a registrational trial for ZILRETTA in OA of the shoulder with data expected mid-year, an interim readout for iovera in spasticity in the first half of next year, and the novel gene therapy PCRX-201 for OA of the knee, which has fully enrolled the first part of its Phase 2 trial and has RMAT designation.
Dec 2, 2025, 6:30 PM
Pacira BioSciences Provides Business and Pipeline Update
PCRX
Guidance Update
New Projects/Investments
Share Buyback
- Pacira BioSciences anticipates generating north of $700 million in revenue and a couple hundred million in adjusted EBITDA this year, alongside $100 million in stock repurchases over recent quarters.
- The company's "Five by 30 Plan" aims for 10% CAGR top-line growth over the next five years, a 5% improvement in gross margin compared to 2024 levels, and reaching 3 million patients by 2030.
- EXPAREL is benefiting from the No Pain Act, which provides separate reimbursement at ASP + six for non-opioid pain therapeutics in outpatient settings for CMS patients.
- Key pipeline updates include ZILRETTA's registrational trial for OA of the shoulder, which was expected to read out mid-2025, and the novel gene therapy PCRX-201's Phase II data readout anticipated approximately late 2026.
Dec 2, 2025, 6:30 PM
Pacira BioSciences Discusses Financial Outlook, Strategic Plan, and Pipeline Updates
PCRX
Guidance Update
New Projects/Investments
Revenue Acceleration/Inflection
- Pacira BioSciences expects to generate north of $700 million in revenue and a couple hundred million in adjusted EBITDA this year, with a capital allocation strategy that includes share repurchases.
- The company's "5 by 30 Plan" aims for 3 million patients benefiting from therapies by 2030, 10% CAGR top-line growth, and a 5% improvement in gross margin over the next five years compared to 2024 levels.
- Key pipeline developments include a registrational trial for Zilretta in OA shoulder with data expected mid-2025, an interim readout for iovera in spasticity in the first half of 2026, and phase 2 data for PCRX-201 (gene therapy for OA knee) around late 2026.
- The No Pain Act is expected to reinvigorate Exparel's growth by providing separate reimbursement at ASP + 6 for outpatient CMS patients.
Dec 2, 2025, 6:30 PM
Pacira BioSciences Files EXPAREL Patent Infringement Lawsuits
PCRX
Legal Proceedings
- Pacira BioSciences has initiated patent infringement lawsuits against The WhiteOak Group, Inc. and Qilu Pharmaceutical (Hainan) Co., Ltd. concerning its drug EXPAREL®.
- These lawsuits have triggered a 30-month stay of final FDA approval for the generic companies' Abbreviated New Drug Applications (ANDAs) under the Hatch Waxman Act.
- EXPAREL is protected by 21 patents, with expiration dates extending to January 22, 2041, and July 2, 2044.
Nov 26, 2025, 9:01 PM
Pacira Provides 2025 Financial Outlook and Updates on Product Growth and Pipeline
PCRX
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Pacira projects 2025 revenue to be north of $700 million, around $750 million, with Exparel sales exceeding $500 million, and EBITDA expected to be around $200 million.
- Exparel volume growth accelerated throughout 2025, with 3% in Q1, 6% in Q2, and 9% in Q3, driven by the "no pain" reimbursement catalyst for Medicare outpatient settings. The company expects over 100 million lives to be covered under no pain-like policies by year-end.
- The company is advancing its pipeline, with PCRX-201, a gene therapy for osteoarthritis of the knee, having completed Phase 1 and fully enrolled Phase 2A, with top-line results anticipated by the end of 2026.
- Gross margins have improved, historically around 76%, now guided to the 80s, due to the transition to a 200-liter manufacturing process for Exparel.
- Pacira aims for a double-digit compounded annual growth rate and a five-point margin expansion by 2030 as part of its "5x30" strategic goals.
Nov 18, 2025, 1:30 PM
Pacira BioSciences Discusses 2025 Financial Outlook, Exparel Growth, and Pipeline Progress
PCRX
Guidance Update
Revenue Acceleration/Inflection
New Projects/Investments
- Pacira BioSciences projects 2025 revenue to be north of $700 million, with Exparel sales exceeding $500 million, and EBITDA around $200 million.
- Exparel's volume growth accelerated in 2025, with year-over-year increases of 3% in Q1, 6% in Q2, and 9% in Q3, driven by the "no pain" Medicare reimbursement catalyst, with expectations for double-digit sales growth in 2026.
- The company is on track to achieve over 100 million lives covered by "no pain-like policies" by the end of 2025 and has improved gross margins from 76% to the 80s due to manufacturing process enhancements.
- Pacira is advancing its pipeline with PCRX-201, a gene therapy for osteoarthritis of the knee, having fully enrolled its Phase IIA study with top-line results anticipated by the end of 2026.
Nov 18, 2025, 1:30 PM
Pacira BioSciences Stockholder Calls for Immediate Sale of Company
PCRX
M&A
Share Buyback
Executive Compensation
- DOMA Perpetual Capital Management LLC, a significant stockholder with a 6.8% ownership stake in Pacira BioSciences, has urged the company's Board of Directors to immediately hire bankers and conduct a formal sale process for the business.
- DOMA cites management's underperformance, out-of-control spending, and lack of prudent financial control as reasons, noting that executive stock-based compensation for full-year 2025 could amount to approximately 6% of Pacira's market capitalization.
- The stockholder highlights a 2% year-over-year decline in Zilretta sales through Q3 and an increase of 3% year-over-year in revenues against 36% year-over-year R&D increase and 25% year-over-year SG&A increase as evidence of financial mismanagement.
- DOMA estimates a potential sale valuation of approximately $2.7 billion, which could translate to around $66 per share or more, representing about three times the current stock price.
- DOMA also recommends that the Board cut costs, put new M&A and development programs on hold, and use all free cash flow for buybacks, including completing the $300 million share repurchase and initiating a new one.
Nov 11, 2025, 1:09 AM
Pacira BioSciences Reports Q3 2025 Results and Updates 2025 Guidance
PCRX
Earnings
Guidance Update
Share Buyback
- Pacira BioSciences reported Q3 2025 total revenue of $180 million, with Non-GAAP Gross Margins of 82% and Adjusted EBITDA of $49 million.
- The company updated its 2025 financial guidance, revising total revenue to $725-735 million and Non-GAAP Gross Margins to 80-82%.
- As part of its "5x30" strategy, Pacira is advancing its pipeline with 5 novel programs, including the in-licensing of AMT-143 for postsurgical pain, with Phase 2 expected to begin in 2026.
- The EXPAREL franchise is protected by 21 Orange Book listed patents, providing exclusivity runways until January 2041 and July 2044.
- Pacira executed an additional $50 million share repurchase in Q3 2025, with $200 million remaining under the current authorization.
Nov 6, 2025, 9:30 PM
Pacira Reports Q3 2025 Revenue Growth and Increased Gross Margin Guidance
PCRX
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Pacira reported a 6% year-over-year revenue increase in Q3 2025, with Exparel sales reaching $139.9 million and a 9% year-over-year volume increase. ZILRETTA and iovera also contributed with sales of $29.0 million and $6.5 million, respectively.
- The company's non-GAAP gross margin improved to 82% in Q3 2025, leading to an increase in full-year 2025 gross margin guidance to 80%-82%. Adjusted EBITDA for the quarter was $49.4 million.
- PCRX ended the quarter with approximately $246 million in cash and investments and repurchased $50 million of common stock, retiring approximately 2 million shares.
- Strategic initiatives included advancing the 5x30 growth strategy, in-licensing AMT 143, concluding enrollment for Part A of the PCRX 201 Phase 2 study ahead of schedule, and listing the 21st Exparel patent. Full-year 2025 revenue guidance was narrowed to $725 million-$735 million.
Nov 6, 2025, 9:30 PM
Pacira BioSciences Reports Q3 2025 Financial Results and Updates Full-Year Guidance
PCRX
Earnings
Guidance Update
Share Buyback
- Pacira BioSciences reported total revenues of $179.5 million for the third quarter of 2025, an increase from $168.6 million in the third quarter of 2024, driven by 9% EXPAREL volume growth.
- The company achieved GAAP net income of $5.4 million, or $0.12 per share, in Q3 2025, compared to a GAAP net loss of $143.5 million, or $(3.11) per share, in Q3 2024.
- Pacira updated its full-year 2025 guidance, narrowing total revenue to $725 million to $735 million (previously $730 million to $750 million) and increasing non-GAAP gross margin guidance to 80% to 82% (previously 78% to 80%).
- During the third quarter of 2025, the company repurchased 2.0 million shares of common stock for $50.0 million, with $200.0 million remaining on its share repurchase authorization at September 30, 2025.
- Key business developments include an exclusive worldwide license agreement for AMT-143 with a $5.0 million upfront payment and the issuance of a new EXPAREL patent (No. 12,370,142) in August 2025, which expires in July 2044.
Nov 6, 2025, 9:04 PM
Quarterly earnings call transcripts for Pacira BioSciences.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more